SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
American Journal of Alzheimer's Disease and Other Dementias®
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Modrego, P. J.
Right arrow Articles by Sarasa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Modrego, P. J.
Right arrow Articles by Sarasa, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Clinical Significance of Plasmatic Amyloid Aβ-40 Peptide Levels in Alzheimer's Disease Patients Treated With Galantamine

Pedro J. Modrego, MD

Neurology Department, Miguel Servet University Hospital, pmodrego{at}salud.aragon.es

Inmaculada Monleon, ChD

Araclon Biotech University of Zaragoza

Manuel Sarasa, PhD

Laboratory of Neurobiology, University of Zaragoza, Zaragoza, Spain

To date there are no conclusive reports on the usefulness of determining amyloid peptides in the serum of patients with Alzheimer's disease (AD). Only anecdotal works deal with the changes in the peptides produced by cholinesterase inhibitors. In this study, the authors investigated and studied the clinical significance of plasmatic Aβ-40 and Aβ-42 peptide levels in a series of 34 consecutive patients with AD. The baseline levels of the Aβ-40 peptide correlated negatively with the Mini Examen Cognoscitivo (Spanish version of the Mini-Mental test) score. Complete follow-up was possible in 22 patients. After 6 months of treatment with galantamine, the mean Aβ-40 peptide levels decreased from 31.86 to 24.22 pg/mL. The baseline levels of Aβ-40 were predictive of response to treatment in the Alzheimer's Disease Assessment Scale—Cognitive Subscale. The authors conclude that determining plasmatic Aβ-40 peptide levels could be useful in predicting and monitoring response to treatment in AD.

Key Words: Alzheimer disease • plasmatic Aβ-40 peptide

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 23, No. 3, 286-290 (2008)
DOI: 10.1177/1533317507313675
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




Advertisement